In Vitro Toxicity Services

Identify Potential Liability Issues in the Early Stages of Drug Discovery

Drug-induced toxicity is a primary cause of failure for drug candidates during preclinical and clinical testing and a significant reason for approved drugs being removed from the market. Initial toxicity tests, which largely rely on animal studies, are essential during the nonclinical phase of development. Despite the valuable safety data these animal models provide, they are often costly, low-throughput, and can lack precise predictability of human biology and pathophysiology due to species differences.

In response to the growing need for early-stage in vitro toxicity testing, WuXi Biology provides a suite of toxicity assays at the cellular level. Using advanced technologies like conventional and automated patch-clamp and high content screening (HCS), these assays can be applied to your lead ID and optimization strategy. The result is a comprehensive analysis of toxicity severity and specificity, guiding candidate compounds through the planning and execution of downstream in vivo tests.

In Vitro Toxicity Services

Download